What is the market doing?
What the tape says about XERS
Xeris Biopharma Holdings, Inc. is +32% over the past year while the S&P 500 is +23%: 9.0 points ahead of the market.
+32%
1-year return · S&P 500 +23%
- vs 200-day average
- +23%
vs 200-day average · a clear uptrend
- RSI (14)
- 78
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- −12%
Below its 52-week high
Details›
- Last close2026-08-26
- $8.68
- 1 monthS&P 500 +3.7%
- +3.1%
- 1 yearS&P 500 +23%
- +32%
- 5 yearsS&P 500 +87%
- +184%
- vs 50-day average$7.74
- +12%
- 52-week high
- $9.90
- 52-week low
- $5.29
- Annualised volatility
- 56%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-06-30
- −$301K
| Year | Return |
|---|---|
| 2026 (year to date) | +11% |
| 2025 | +132% |
| 2024 | +44% |
| 2023 | +77% |
| 2022 | −55% |
| 2021 | −40% |
| 2020 | −30% |
| 2019 | −59% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 3 of 8 | −7.0% |
| Feb | 8 | 5 of 8 | −3.1% |
| Mar | 8 | 4 of 8 | −3.3% |
| Apr | 8 | 4 of 8 | +3.4% |
| May | 8 | 6 of 8 | +15% |
| Jun | 8 | 4 of 8 | −3.4% |
| Jul | 9 | 5 of 9 | +0.40% |
| Aug | 9 | 6 of 9 | +19% |
| Sep | 8 | 3 of 8 | −6.4% |
| Oct | 8 | 4 of 8 | −0.41% |
| Nov | 8 | 4 of 8 | −2.5% |
| Dec | 8 | 5 of 8 | +5.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers - Specialty & Generic
Ranks #12 of 28 by Smart Score